DJIA 18,086.65 48.68 0.27%
NASDAQ 5,062.41 2.17 0.04%
S&P 500 2,110.95 2.03 0.10%
market minute promo

Merck & Co., Inc. (NYSE: MRK)



company name or ticker
Company Photos
(Click to zoom)

Morgan Stanley Awaits This Merck Data

Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog

Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog

AACR - Solid Tumour CAR-T Foray Lives Up To Its Low-Key Billing

Health Care Sector Update for 04/20/2015: TLOG,GENE,AMPE, MRK

Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals

Midday Update: Stocks Reversing Friday Sell-Off After China Trims Reserve Requirements, Raises Liqui

Midday Update: Stocks Reversing Friday Sell-Off After China Trims Reserve Requirements, Raises Liquidity

Morning Market Gainers

Is Bristol-Myers Squibb. Co. About to Fall Apart?

Bristol-Myers Squibb is pinning its future on a new class of drugs that could be game-changers in the fight against cancer. The Street, though, may be wildly overestimating their commercial potential. Here's why.

Best Pure Play Investment in Cancer Drugs

Global cancer drug sales could soon soar past $100 billion, making this pure play in cancer drugs a stock you should seriously consider owning.
See More Articles...